The Hempshire Group, Inc. (HMPSF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
The Hempshire Group, Inc. (HMPSF) trades at $0.19 with AI Score 41/100 (Grade C). The Hempshire Group, Inc. is involved in sourcing, manufacturing, branding, and processing pharmaceutical-grade hemp and CBD products. Market cap: $15.68M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for HMPSF: HMPSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HMPSF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HMPSF: the 1 perspectives are evenly split.
How is this calculated? →The Hempshire Group, Inc. (HMPSF) Healthcare & Pipeline Overview
The Hempshire Group, Inc., established in 2019, focuses on the pharmaceutical-grade hemp and CBD product sector. Operating with a small team, the company engages in sourcing, manufacturing, and branding, distinguishing itself in the competitive specialty and generic drug manufacturing industry through its focus on hemp-derived products.
What Is the Investment Thesis for HMPSF?
The Hempshire Group, Inc. presents a high-risk, high-reward investment profile. The company's negative P/E ratio of -1.97 and a profit margin of -7300.9% indicate significant challenges in achieving profitability. However, its gross margin of 28.8% suggests potential in its core operations if costs can be managed effectively. A beta of 0.12 indicates low volatility compared to the market. Growth catalysts include potential expansion of its product line and increased market penetration in the growing CBD sector. The company's small size and limited resources pose risks, but successful execution of its business plan could lead to substantial returns. Investors should carefully consider the company's financial position and competitive landscape before investing.
Based on FMP financials and quantitative analysis
HMPSF Key Highlights
- Market capitalization of $15.68M, indicating a micro-cap company.
- Negative P/E ratio of -1.97, reflecting current losses.
- Profit margin of -7300.9%, highlighting significant operational inefficiencies.
- Gross margin of 28.8%, suggesting potential for profitability with improved cost management.
- Beta of 0.12, indicating lower volatility compared to the overall market.
Who Are HMPSF's Competitors?
HMPSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMHV American Hemp Ventures, Inc. | $0.98 | +0.00% | $16.47M | 46 |
| ATHJF Antisense Therapeutics Limited | $0.01 | -76.00% | $19.64M | 57 |
| BFFTF Biofrontera AG | $0.33 | -95.24% | $19.35M | 46 |
| GRAMF TPCO Holding Corp. | $0.16 | -15.36% | $20.12M | 42 |
| MGCLF MGC Pharmaceuticals Limited | $0.27 | +2.88% | $12.11M | 46 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HMPSF's Key Strengths?
- Focus on pharmaceutical-grade hemp and CBD products.
- Established brand in a growing market.
- Proprietary processing techniques.
- Experienced management team.
What Are HMPSF's Weaknesses?
- Small size and limited resources.
- Negative profitability and high losses.
- Reliance on a niche market.
- Limited distribution network.
What Could Drive HMPSF Stock Higher?
- Potential regulatory changes in the CBD market could create new opportunities for Hempshire.
- Expansion of product line to include new CBD-infused products.
- Strategic partnerships with established pharmaceutical companies or retailers.
What Are the Key Risks for HMPSF?
- Financial-distress signal — its Altman Z-Score of -21.91 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition in the CBD market could erode market share.
- Regulatory uncertainty and changing laws could negatively impact operations.
- Fluctuations in hemp prices could affect profitability.
- Limited financial resources may hinder growth initiatives.
- Negative P/E ratio and profit margin indicate financial instability.
What Are the Growth Opportunities for HMPSF?
- Expansion of Product Line: Hempshire can expand its product line to include a wider range of CBD-infused products, such as topicals, edibles, and beverages. The global CBD market is projected to reach $55.79 billion by 2028, offering significant growth potential. By diversifying its offerings, Hempshire can attract a broader customer base and increase revenue streams. Successful product development and marketing will be crucial for capturing market share.
- Strategic Partnerships: Forming strategic partnerships with established pharmaceutical companies or retailers could provide Hempshire with access to wider distribution networks and increased brand visibility. Collaborations can also facilitate research and development efforts, leading to innovative product formulations. The timeline for establishing such partnerships is dependent on negotiation and due diligence processes, but could yield significant benefits within the next 1-2 years.
- International Expansion: Exploring opportunities to expand into international markets, particularly in Europe and Asia, where the demand for CBD products is growing, represents a significant growth driver. Navigating regulatory requirements and establishing distribution channels in new markets will be essential for successful international expansion. This initiative could take 2-3 years to fully implement, but offers long-term growth potential.
- Focus on Research and Development: Investing in research and development to create novel CBD formulations and delivery methods can provide Hempshire with a competitive advantage. Developing proprietary technologies and intellectual property can also attract investment and partnership opportunities. The timeline for R&D initiatives can vary depending on the complexity of the projects, but could yield significant results within 3-5 years.
- Direct-to-Consumer Sales: Establishing a strong online presence and direct-to-consumer sales channel can improve margins and provide greater control over the customer experience. Investing in e-commerce infrastructure and digital marketing can drive online sales and build brand loyalty. This initiative can be implemented relatively quickly, with noticeable results within the next 6-12 months.
What Opportunities Does HMPSF Have?
- Expansion of product line.
- Strategic partnerships with larger companies.
- International market expansion.
- Increased research and development.
What Threats Does HMPSF Face?
- Intense competition in the CBD market.
- Regulatory uncertainty and changing laws.
- Fluctuations in hemp prices.
- Economic downturn affecting consumer spending.
What Are HMPSF's Competitive Advantages?
- Focus on pharmaceutical-grade quality.
- Specialization in hemp and CBD products.
- Established branding and marketing strategies.
- Proprietary processing techniques.
What Does HMPSF Do?
The Hempshire Group, Inc., founded in 2019 and based in Palm Springs, California, operates within the healthcare sector, specifically in the specialty and generic drug manufacturing industry. The company is involved in the sourcing, manufacturing, branding, and processing of pharmaceutical-grade hemp and CBD products. Hempshire's focus is on creating and distributing products derived from hemp, positioning itself in a niche market within the broader pharmaceutical landscape. The company's operations encompass the entire product lifecycle, from sourcing raw materials to manufacturing finished goods and establishing brand recognition. With a small team of 8 employees, Hempshire navigates the complexities of the pharmaceutical industry, targeting consumers seeking hemp and CBD-based health and wellness solutions. The company's strategic focus on pharmaceutical-grade products underscores a commitment to quality and regulatory compliance, differentiating it from other players in the hemp and CBD market.
What Products and Services Does HMPSF Offer?
- Sources pharmaceutical-grade hemp.
- Manufactures CBD products.
- Brands and markets its products.
- Processes hemp for various applications.
- Focuses on the healthcare sector.
- Operates in the specialty and generic drug manufacturing industry.
How Does HMPSF Make Money?
- Sourcing high-quality hemp.
- Manufacturing CBD products.
- Branding and marketing for direct sales and distribution.
- Processing hemp for pharmaceutical applications.
What Industry Does HMPSF Operate In?
The Hempshire Group, Inc. operates in the specialty and generic drug manufacturing industry, which is experiencing growth driven by increasing demand for alternative medicines and wellness products. The CBD market, in particular, is expanding rapidly, but faces regulatory uncertainty and intense competition. Hempshire's focus on pharmaceutical-grade hemp and CBD products positions it within a niche segment that emphasizes quality and compliance. The company competes with both established pharmaceutical companies and smaller, specialized CBD manufacturers. Success in this market requires effective branding, distribution, and adherence to evolving regulatory standards.
Who Are HMPSF's Key Customers?
- Consumers seeking hemp-based wellness products.
- Patients looking for alternative treatments.
- Retailers and distributors of health and wellness products.
The Hempshire Group, Inc. (HMPSF) Valuation Context
Valued at $15.68M, HMPSF is classified as a micro-cap stock. Relative to its peer group, HMPSF's quantitative score of 41/100 is roughly in line with the peer average of 47/100.
Key Financial Metrics
Its free cash flow yield is -19.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.52 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -50.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
The Hempshire Group, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -21.91 places it in the distress zone, a signal of elevated financial risk.
HMPSF Financials
Bull Case vs Bear Case
Bull Case
- Focus on pharmaceutical-grade hemp and CBD products.
- Established brand in a growing market.
- Proprietary processing techniques.
- Experienced management team.
Bear Case
- Small size and limited resources.
- Negative profitability and high losses.
- Reliance on a niche market.
- Limited distribution network.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
HMPSF Latest News
No recent news available for HMPSF.
HMPSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HMPSF.
Price Targets
Wall Street price target analysis for HMPSF.
HMPSF MoonshotScore
What does this score mean?
The MoonshotScore rates HMPSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Shawn Balaghi
CEO
Shawn Balaghi is the CEO of The Hempshire Group, Inc. His background includes experience in managing and developing businesses, with a focus on the healthcare and wellness sectors. He has been instrumental in guiding the company's strategic direction and overseeing its operations. Balaghi's leadership is focused on driving innovation and growth within the competitive CBD market.
Track Record: Under Shawn Balaghi's leadership, The Hempshire Group, Inc. has focused on establishing a presence in the pharmaceutical-grade hemp and CBD market. Key milestones include developing a range of CBD products and establishing partnerships with distributors. Balaghi's strategic decisions have aimed at positioning the company for long-term growth and success in the evolving CBD industry.
HMPSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that The Hempshire Group, Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may not be subject to the same level of scrutiny as those listed on major exchanges like the NYSE or NASDAQ. This tier is generally associated with higher risk and lower liquidity compared to listed exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure requirements.
- Lower liquidity and potential price volatility.
- Higher risk of fraud or mismanagement.
- Potential for delisting or trading suspension.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's compliance with regulatory requirements.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Established business operations since 2019.
- Focus on pharmaceutical-grade products.
- Presence in the growing CBD market.
- Active engagement with investors and stakeholders.
HMPSF Healthcare Stock FAQ
What does The Hempshire Group, Inc. do?
The Hempshire Group, Inc. engages in the sourcing, manufacturing, branding, and processing of pharmaceutical-grade hemp and CBD products. Operating in the healthcare sector, the company focuses on creating and distributing products derived from hemp, positioning itself in a niche market within the broader pharmaceutical landscape. Hempshire's business model encompasses the entire product lifecycle, from sourcing raw materials to manufacturing finished goods and establishing brand recognition. The company targets consumers seeking hemp and CBD-based health and wellness solutions.
What do analysts say about HMPSF stock?
As of 2026-03-17, there is no readily available analyst consensus on HMPSF stock due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio and profit margin, indicate financial challenges. Growth considerations include the potential for expansion in the CBD market and strategic partnerships. Investors should conduct thorough due diligence and consider the risks associated with investing in micro-cap OTC stocks before making any investment decisions.
What are the main risks for HMPSF?
The main risks for The Hempshire Group, Inc. include intense competition in the CBD market, regulatory uncertainty and changing laws, fluctuations in hemp prices, and limited financial resources. The company's negative P/E ratio and profit margin also indicate financial instability. As an OTC-listed company, HMPSF faces additional risks related to liquidity, disclosure requirements, and regulatory oversight. Investors should carefully consider these risks before investing in HMPSF stock.
What are the key factors to evaluate for HMPSF?
The Hempshire Group, Inc. (HMPSF) holds an AI score of 41/100 (low). Not financial advice.
How frequently does HMPSF data refresh on this page?
HMPSF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HMPSF's recent stock price performance?
The Hempshire Group, Inc. (HMPSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on pharmaceutical-grade hemp and CBD products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HMPSF overvalued or undervalued right now?
Valuing The Hempshire Group, Inc. (HMPSF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HMPSF?
Before investing in The Hempshire Group, Inc. (HMPSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be fully up-to-date.